Ensol Biosciences (XKRX:140610) Accounts Payable & Accrued Expense : ₩546 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Accounts Payable & Accrued Expense?

Ensol Biosciences's quarterly accounts payable & accrued expense increased from Dec. 2022 (₩204 Mil) to Dec. 2023 (₩858 Mil) but then declined from Dec. 2023 (₩858 Mil) to Dec. 2024 (₩546 Mil).

Ensol Biosciences's annual accounts payable & accrued expense increased from Dec. 2022 (₩204 Mil) to Dec. 2023 (₩858 Mil) but then declined from Dec. 2023 (₩858 Mil) to Dec. 2024 (₩546 Mil).

Ensol Biosciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Ensol Biosciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Accounts Payable & Accrued Expense Chart

Ensol Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

241.70

190.71

203.98

858.46

546.37

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial						241.70	190.71	203.98	858.46	546.37

Ensol Biosciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines